Clinical trial
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
NCT00295685 · Digestive & Liver Disease Specialists, Other · Completed
Key facts
| NCT number | NCT00295685 |
|---|---|
| Title | Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD |
| Official title | Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study |
| Lead sponsor | Digestive & Liver Disease Specialists, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | GERD |
| Intervention type | Drug |
| Interventions | Antacids |
| Enrollment | 50 |
| Start date | Oct 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Feb 24, 2006 |
| Last update posted | Feb 25, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: